Core Viewpoint - Company Zhuhai Biotech-B (02509) announced a share buyback plan, spending approximately HKD 999,400 to repurchase 48,800 shares on November 18, 2025 [1] Summary by Category - **Share Buyback Details** - The company will repurchase a total of 48,800 shares [1] - The total expenditure for this buyback is approximately HKD 999,400 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇荃信生物醫藥股份有限公司 呈交日期： 2025年11月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02509 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包 ...

格隆汇11月17日丨荃信生物-B(02509.HK)公告，11月17日耗资71万港元回购3.5万股。 ...

Core Viewpoint - The company, 荃信生物-B (02509), announced a share buyback on November 17, 2025, spending HKD 711,900 to repurchase 34,600 shares at a price range of HKD 20.16 to HKD 20.72 per share [1] Summary by Categories Company Actions - 荃信生物-B has executed a share buyback program, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback amounts to HKD 711,900, reflecting the company's financial strategy [1] Share Performance - The repurchase price per share ranges from HKD 20.16 to HKD 20.72, which may suggest the company's valuation assessment of its own shares [1] - The total number of shares repurchased is 34,600, which could impact the company's share liquidity and market perception [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇荃信生物醫藥股份有限公司 呈交日期： 2025年11月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02509 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包 ...

Group 1 - Tsugami Machine Tool China (01651) saw a rise of over 5.4% due to increased demand for high-precision machine tools in emerging sectors like new energy vehicles and artificial intelligence as China's economy gradually recovers [1] - Black Sesame Intelligence (02533) increased by over 2.2% after announcing that its flagship product, the Huashan A1000 automotive-grade high-performance driving assistance chip, has been successfully integrated into Desay SV's new low-speed unmanned vehicle brand "Chuanxing Zhiyuan" S6 series [1] - Zai Xin Bio-B (02509) rose over 5.8% after receiving clinical trial approval for its self-developed long-acting dual antibody QX027N injection, intended for the treatment of asthma and atopic dermatitis [1] - CanSino Biologics (06185) increased nearly 5% as it announced the initiation of Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia [1] Group 2 - Kingsray Biotechnology (01548) rebounded over 4.48% following the financial performance disclosure of its joint venture Legend Biotech for the third quarter ending September 30, 2025 [2] - Fuhong Hanlin (02696) rose over 5.2% after its PD-1 antibody drug, Surufilumab injection, was proposed for breakthrough therapy designation for use in combination with chemotherapy for gastric cancer [2] - Yidu International Holdings (00259) increased over 6% amid uncertainty regarding the impact of an undisclosed event on its financial statements for the year ending March 31, 2025 [2] Group 3 - Reshaping Energy (02570) surged nearly 60%, with a rise of 55.03%, following announcements from the National Energy Administration encouraging the use of green hydrogen in coal chemical projects and plans to promote over 2,000 hydrogen vehicles in Shandong Province [3] - Laika Pharmaceuticals-B (02105) saw a reverse increase of over 10.3% after granting Qilu Pharmaceutical exclusive rights for research, development, and commercialization of the breast cancer candidate drug LAE002 (afuresertib) in China [3] Group 4 - WMCH GLOBAL (08208) resumed trading with a rise of over 50%, increasing by 57.45% after announcing the sale of approximately 384 million shares, representing about 53.297% of its issued share capital [4] Group 5 - U.S. stock market opened lower, with the Nasdaq dropping 2.04%, as major tech stocks like Nvidia, AMD, and Tesla saw declines [5] - Tencent reached an agreement with Apple regarding payment processing for WeChat mini-games, potentially opening new revenue streams for Apple [5] - Mangoceuticals (MGRX.US) plummeted 32.39% after announcing partnerships with Eli Lilly and Novo Nordisk to provide users with weight loss medications [6] - Fannie Mae (FNMA.US) fell 9.82%, with a two-day cumulative drop of 20%, amid investigations into the actions of the Federal Housing Finance Agency director [6] - Disney (DIS.US) dropped 7.75% despite strong performance in streaming and theme parks, as upcoming major film releases are expected to impact first-quarter performance [6]

Core Viewpoint - 荃信生物-B (02509.HK) experienced a significant increase in stock price, rising over 8% in early trading, indicating positive market sentiment towards the company [2] Group 1 - The stock price of 荃信生物-B reached 22.08 HKD, reflecting an increase of 8.45% [2] - The trading volume amounted to 560.3 million HKD, suggesting active investor interest [2]

Core Viewpoint - The company, Qianxin Biopharmaceuticals-B (02509), has seen its stock price rise over 8% following the announcement of clinical trial approval for its long-acting dual antibody QX027N, aimed at treating asthma and atopic dermatitis [1] Group 1: Clinical Developments - Qianxin Biopharmaceuticals has received implied clinical trial approval from the National Medical Products Administration for its self-developed long-acting dual antibody QX027N [1] - The clinical approval marks the entry of the company's innovative dual antibody matrix into the clinical stage for autoimmune and allergic diseases [1] Group 2: Strategic Partnerships - On October 28, Qianxin Biopharmaceuticals announced a global exclusive collaboration and licensing agreement with Roche for its self-developed long-acting autoimmune dual antibody QX031N [1] - Under the agreement, Roche will have exclusive rights for research, development, registration, production, and commercialization of QX031N globally [1] - Qianxin Biopharmaceuticals will receive an upfront payment of $75 million, with potential milestone payments of up to $995 million and tiered royalties on future product sales [1]

Core Viewpoint - The stock of Zai Lab Limited (荃信生物-B) surged over 8% following the announcement of its long-acting dual antibody QX027N receiving clinical trial approval from the National Medical Products Administration, marking a significant advancement in the company's innovation pipeline for autoimmune and allergic diseases [1] Group 1: Clinical Developments - Zai Lab's QX027N injection is intended for the treatment of asthma and atopic dermatitis, indicating the company's commitment to addressing unmet medical needs in these areas [1] - The clinical trial approval signifies the official entry of the company's innovative dual antibody matrix into the clinical stage [1] Group 2: Strategic Partnerships - On October 28, Zai Lab announced a global exclusive collaboration and licensing agreement with Roche for its long-acting autoimmune dual antibody QX031N [1] - Under the agreement, Roche will gain exclusive rights for research, development, registration, production, and commercialization of QX031N globally [1] - Zai Lab will receive an upfront payment of $75 million, with potential milestone payments of up to $995 million, along with tiered royalties on future product sales [1]

Core Viewpoint - The stock of Zai Lab Limited (02509) rose over 8% following the announcement of clinical trial approval for its self-developed long-acting dual antibody QX027N, aimed at treating asthma and atopic dermatitis [1] Group 1: Clinical Developments - Zai Lab's long-acting dual antibody QX027N injection received implied clinical trial approval from the National Medical Products Administration, marking a significant step into clinical stages for the company's innovative dual antibody matrix in autoimmune and allergic diseases [1] - The company also announced a global exclusive collaboration and licensing agreement with Roche for its self-developed long-acting autoimmune dual antibody QX031N, granting Roche rights for research, development, registration, production, and commercialization [1] Group 2: Financial Aspects - Under the agreement with Roche, Zai Lab will receive an upfront payment of $75 million, with potential milestone payments of up to $995 million, along with tiered royalties on future product sales [1]